Ross Acquisition Corp II (NYSE:ROSS) announced this afternoon that it has mutually terminated its combination with drug developer APRINOIA, effective immediately.
The parties did not disclose why they decided to nix the deal and did not provide further details.
Ross II inked its $319 million business combination with APRINOIA in January, originally bringing about $350.6 million into the deal from its trust. It supplemented this with $12.5 million in convertible notes, $7.5 million of which were to be funded by an affiliate of the SPAC’s CEO, President and Chairman Wilbur Ross, and APRINOIA was expected to receive a $10 million strategic investment from a pharmaceutical partner.
However, the SPAC saw 81.5% of its trust redeemed during previous extension meetings, leaving it with $65.3 million post-vote. It remains unclear whether Ross II will continue to search for an alternative target to combine with or liquidate, but it currently faces a deadline just weeks away on September 16.
Cambridge, Massachusetts-based APRINOIA is developing treatments and diagnostic tools for Alzheimer’s and Parkinson’s that target the toxic proteins that accelerate the diseases’ progression.
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....
1RT Acquisition Corp. (NASDAQ:ONCHU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ONCHU”, Wednesday, July 2, 2025. The new SPAC plans to target company in the digital asset ecosystem involved in the creation, storage, exchange or management of such assets, whether...
D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...